Хайлтын үр дүнгүүд

Cardiovascular and pulmonary adverse events in patients treated with <i><scp>BCR</scp>‐<scp>ABL</scp></i> inhibitors: Data from the <scp>FDA</scp> Adverse Event Reporting System -н Jorge E. Cortés, Michael J. Mauro, Juan Luis Steegmann, Giuseppe Saglio, Rachpal Malhotra, Jon Ukropec, Nicola Wallis

Бүрэн текст авах Бүрэн текст авах

FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors -н Catherine C. Smith, Kevin Lin, Adrian Stecuła, Andrej Šali, Neil P. Shah

Бүрэн текст авах

The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors -н Sara A. Byron, Huaibin Chen, Andreas Wortmann, David Loch, Michael G. Gartside, Farhad Dehkhoda, Steven P. Blais, Thomas A. Neubert, Moosa Mohammadi, Pamela M. Pollock

Бүрэн текст авах

Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia -н Michael S. Khodadoust, Bin Luo, Bruno C. Medeiros, Ryan C. Johnson, Mark D. Ewalt, A S Schalkwyk, Charles D. Bangs, Athena M. Cherry, Sally Arai, Daniel A. Arber, James L. Zehnder, Jason Gotlib

Бүрэн текст авах

Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase -н Tobias Klein, Navratna Vajpai, Jonathan J. Phillips, Gareth M. Davies, Geoffrey A. Holdgate, Chris Phillips, Julie A. Tucker, Richard A. Norman, Andrew D. Scott, Daniel R. Higazi, David C. Lowe, Gary S. Thompson, Alexander L. Breeze

Бүрэн текст авах Бүрэн текст авах

Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study -н Preetesh Jain, Hagop M. Kantarjian, Elias Jabbour, Graciela Nogueras González, Gautam Borthakur, Naveen Pemmaraju, Naval Daver, Evguenia Gachimova, Alessandra Ferrajoli, Steven M. Kornblau, Farhad Ravandi, Susan O’Brien, Jorge E. Cortés

Бүрэн текст авах

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study -н Elias Jabbour, Hagop M. Kantarjian, Farhad Ravandi, Deborah A. Thomas, Xuelin Huang, Stefan Faderl, Naveen Pemmaraju, Naval Daver, Guillermo Garcia‐Manero, Koji Sasaki, Jorge E. Cortés, Rebecca Garris, C. Cameron Yin, Joseph D. Khoury, Jeffrey L. Jorgensen, Zeev Estrov, Zachary S. Bohannan, Marina Konopleva, Tapan M. Kadia, Nitin Jain, Courtney D. DiNardo, William G. Wierda, Vicky Jeanis, Susan O’Brien

Бүрэн текст авах

Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia -н Javid J. Moslehi, Michael W. Deininger

Бүрэн текст авах

Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects -н Narayana I. Narasimhan, David J. Dorer, Katie Niland, Frank G. Haluska, Daryl Sonnichsen

Бүрэн текст авах Бүрэн текст авах

Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities -н Ming Ren, Qin He, Rui Ren, John K. Cowell

Бүрэн текст авах

Evolution of Therapies for Chronic Myelogenous Leukemia -н Fabio P S Santos, Hagop M. Kantarjian, Alfonso Quintás‐Cardama, Jorge E. Cortés

Бүрэн текст авах

Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm -н Elias Jabbour, Hagop M. Kantarjian, Jorge E. Cortés

Бүрэн текст авах

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets -н Uwe Rix, Oliver Hantschel, Gerhard Dürnberger, Lily Rix, Melanie Planyavsky, Nora V. Fernbach, Ines Kaupe, Keiryn L. Bennett, Peter Valent, Jacques Colinge, Thomas Köcher, Giulio Superti‐Furga

Бүрэн текст авах Бүрэн текст авах

Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML -н Georg E. Winter, Uwe Rix, Scott M. Carlson, Karoline V. Gleixner, Florian Grebien, Manuela Gridling, André C. Müller, Florian P. Breitwieser, Martin Bilban, Jacques Colinge, Peter Valent, Keiryn L. Bennett, Forest M. White, Giulio Superti‐Furga

Бүрэн текст авах

Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study -н Neil P. Shah, Moshe Talpaz, Michael W. Deininger, Michael J. Mauro, Ian W. Flinn, Dale L. Bixby, Stephanie Lustgarten, Joseph M. Gozgit, Tim Clackson, Christopher D. Turner, Frank G. Haluska, Hagop M. Kantarjian, Jorge E. Cortés

Бүрэн текст авах Бүрэн текст авах

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors -н Peter Valent, Emir Hadzijusufovic, G. Schernthaner, Dominik Wolf‎, Delphine Réa, Philipp le Coutre

Бүрэн текст авах Бүрэн текст авах

Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study -н Hemanth Naick Banavath, O. P. Sharma, Muthuvel Suresh Kumar, Rathinasamy Baskaran

Бүрэн текст авах Бүрэн текст авах

Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations -н Elie Traer, Nathalie Javidi‐Sharifi, Anupriya Agarwal, Jennifer Dunlap, Isabel English, Jacqueline Martinez, Jeffrey W. Tyner, Melissa Wong, Brian J. Druker

Бүрэн текст авах Бүрэн текст авах

Crenolanib is a selective type I pan-FLT3 inhibitor -н Catherine C. Smith, Elisabeth A. Lasater, Kimberly C. Lin, Qi Wang, Melissa Q. McCreery, Whitney Stewart, Lauren E. Damon, Alexander E. Perl, Grace R. Jeschke, Mayumi Sugita, Martin Carroll, Scott C. Kogan, John Kuriyan, Neil P. Shah

Бүрэн текст авах

Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases -н Els Lierman, Sanne Smits, Jan Cools, Barbara Dewaele, Maria Dębiec‐Rychter, Peter Vandenberghe

Бүрэн текст авах